Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc..
Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody, progress prematurely. By integrating tumor whole-genome and microenvironment single-cell RNA sequencing from upfront phase 2 trials using carfilzomib, lenalidomide and dexamethasone with daratumumab ( NCT03290950 ), we show how distinct genomic drivers including high APOBEC mutational activity, IKZF3 and RPL5 deletions and 8q gain affect clinical outcomes. Furthermore, evaluation of paired bone marrow profiles, taken before and after eight cycles of carfilzomib, lenalidomide and dexamethasone with daratumumab, shows that numbers of natural killer cells before treatment, high T cell receptor diversity before treatment, the disappearance of sustained immune activation (that is, B cells and T cells) and monocyte expansion over time are all predictive of sustained minimal residual disease negativity. Overall, this study provides strong evidence of a complex interplay between tumor cells and the immune microenvironment that is predictive of clinical outcome and depth of treatment response in patients with newly diagnosed multiple myeloma treated with highly effective combinations containing anti-CD38 antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Nature cancer - 4(2023), 12 vom: 07. Dez., Seite 1660-1674 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maura, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 27.12.2023 Date Revised 15.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s43018-023-00657-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364374659 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364374659 | ||
| 003 | DE-627 | ||
| 005 | 20240416232338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43018-023-00657-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM364374659 | ||
| 035 | |a (NLM)37945755 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maura, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2023 | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody, progress prematurely. By integrating tumor whole-genome and microenvironment single-cell RNA sequencing from upfront phase 2 trials using carfilzomib, lenalidomide and dexamethasone with daratumumab ( NCT03290950 ), we show how distinct genomic drivers including high APOBEC mutational activity, IKZF3 and RPL5 deletions and 8q gain affect clinical outcomes. Furthermore, evaluation of paired bone marrow profiles, taken before and after eight cycles of carfilzomib, lenalidomide and dexamethasone with daratumumab, shows that numbers of natural killer cells before treatment, high T cell receptor diversity before treatment, the disappearance of sustained immune activation (that is, B cells and T cells) and monocyte expansion over time are all predictive of sustained minimal residual disease negativity. Overall, this study provides strong evidence of a complex interplay between tumor cells and the immune microenvironment that is predictive of clinical outcome and depth of treatment response in patients with newly diagnosed multiple myeloma treated with highly effective combinations containing anti-CD38 antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 700 | 1 | |a Boyle, Eileen M |e verfasserin |4 aut | |
| 700 | 1 | |a Coffey, David |e verfasserin |4 aut | |
| 700 | 1 | |a Maclachlan, Kylee |e verfasserin |4 aut | |
| 700 | 1 | |a Gagler, Dylan |e verfasserin |4 aut | |
| 700 | 1 | |a Diamond, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Ghamlouch, Hussein |e verfasserin |4 aut | |
| 700 | 1 | |a Blaney, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Ziccheddu, Bachisio |e verfasserin |4 aut | |
| 700 | 1 | |a Cirrincione, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Chojnacka, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yubao |e verfasserin |4 aut | |
| 700 | 1 | |a Siegel, Ariel |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffman, James E |e verfasserin |4 aut | |
| 700 | 1 | |a Kazandjian, Dickran |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Guzman, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Mailankody, Sham |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Urvi A |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Carlyn |e verfasserin |4 aut | |
| 700 | 1 | |a Hultcrantz, Malin |e verfasserin |4 aut | |
| 700 | 1 | |a Scordo, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Gunjan L |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Giralt, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yanming |e verfasserin |4 aut | |
| 700 | 1 | |a Arbini, Arnaldo |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Roshal, Mikhail |e verfasserin |4 aut | |
| 700 | 1 | |a Dogan, Ahmet |e verfasserin |4 aut | |
| 700 | 1 | |a Lesokhin, Alexander M |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Faith E |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, Saad Z |e verfasserin |4 aut | |
| 700 | 1 | |a Korde, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Morgan, Gareth J |e verfasserin |4 aut | |
| 700 | 1 | |a Landgren, Ola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature cancer |d 2020 |g 4(2023), 12 vom: 07. Dez., Seite 1660-1674 |w (DE-627)NLM307030067 |x 2662-1347 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:12 |g day:07 |g month:12 |g pages:1660-1674 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43018-023-00657-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 12 |b 07 |c 12 |h 1660-1674 | ||